Vaxxinity, Inc. announced that Peter Powchik, M.D., will join leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023. He will remain as a member of Vaxxinitys board of directors. Peter will oversee the overall scientific direction of Vaxxinitys platform and programs, and lead the development efforts at Vaxxinity.

Get ready for the next wave of innovative drug science at Vaxxinity. Peter has served an integral role on Vaxxinitys board of directors, and now get the benefit of his extensive knowledge and experience around the development of breakthrough medicines on an even deeper level as he transitions to leadership team. Prior to joining Vaxxinity and its predecessor United Neuroscience, Peter was Senior Vice President, Head of Clinical Development at Regeneron Pharmaceuticals from 2006 to 2018, where he oversaw the development of Regenerons first seven approved drugs and helped to build its development and regulatory infrastructure.

Peter led the development of multiple products to licensure including Eylea, Kevzara, Arcalyst, Dupixent, and Praluent against PCSK9 for hypercholesterolemia. He also served various roles in clinical development, including at Chugai Pharma USA; Novartis, where he oversaw the development and approval of Ritalin LA and Focalin; and Sepracor, where he initiated the development of Lunesta. He is a board-certified psychiatrist trained at NYU School of Medicine, Mount Sinai Medical Center (NYC), and Columbia University College of Physicians and Surgeons.

Ulo Palm, M.D., will transition from Chief Medical Officer of Vaxxinity to senior advisor effective October 1, 2023. Under his guidance, Vaxxinity brought two new programs to the clinic and successfully completed a Phase 3 COVID-19 trial and Phase 1 Parkinsons disease trial.